Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Frank Vinluan / medcitynews - Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia,…
AI Summary: Merck announced a definitive deal to acquire Terns Pharmaceuticals for about $6.7 billion, gaining a promising leukemia drug candidate and bolstering its oncology pipeline. The transaction aims to combine Merck’s late‑stage development and commercialization capabilities with Terns’ targeted therapy assets to compete in hematologic malignancies.
Pfizer Lyme vaccine candidate heads to FDA
Ella Jeffries / beckershospitalreview - Pfizer and Valneva’s investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease among individuals age 5 and older, according to topline phase 3 trial results. The prespecified analysi…
AI Summary: Pfizer is advancing a Lyme disease vaccine toward FDA submission despite a messy late‑stage picture: efficacy signals above 70% were reported while a pivotal trial missed its primary endpoint and struggled with low case numbers. Regulators must weigh public health need against statistical nuance as the company pushes for licensure.
A blood test may tailor breast cancer treatment for older women
medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …
AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.
- EBCC15: Less overtreatment through personalized radiotherapy and surveillance (4)
- Liquid biopsies and sensors advancing cancer detection beyond breast (4)
- Other: biology and global burden stories (3)
- Ultrasensitive ctDNA: tailoring breast cancer care for older patients (5)
- All Other Stories
EBCC15: Less overtreatment through personalized radiotherapy and surveillance
Liquid biopsies and sensors advancing cancer detection beyond breast
Other: biology and global burden stories
Ultrasensitive ctDNA: tailoring breast cancer care for older patients
All Other Stories
Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Elizabeth Cairns / endpoints - Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study. The triple-G ...
AI Summary: Eli Lilly’s third‑generation GLP‑1 candidate reported Phase 3 data demonstrating significant weight loss and A1C reductions, with efficacy appearing comparable to existing therapies like Mounjaro. The results sharpen competition in the GLP‑1 market and raise questions about pricing, access and who gets first dibs on the next blockbuster injection.
- At clinics: GLP‑1 demand reshaping access, care and pricing (5)
- In labs: oral pills and novel GLP‑1 delivery approaches (4)
- On the ground: Lilly's triple‑G rivaling Mounjaro in trials (3)
- Other: clinical oddities, surgical implications and pipeline setbacks (5)
At clinics: GLP‑1 demand reshaping access, care and pricing
In labs: oral pills and novel GLP‑1 delivery approaches
On the ground: Lilly's triple‑G rivaling Mounjaro in trials
Other: clinical oddities, surgical implications and pipeline setbacks
Engineered tissue offers hope for children born with 'missing' esophagus
medicalxpress - Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown esophagus—the food pipe—shown to safely replace a full section of the organ and restore normal function, including swallowing, in a gr…
AI Summary: Researchers report progress developing lab-grown esophageal tissue to treat children born with congenital absence or severe damage of the esophagus. Early preclinical and surgical work demonstrates that engineered tissue constructs can be implanted and integrated, offering a potential alternative to complex reconstructions — a promising step for tiny patients with very big problems.
Rob Winn Appointed Director of NCI-Designated Fox Chase Cancer Center
oncodaily - Fox Chase Cancer Center shared a post on LinkedIn: “Temple Health – Temple University Health System today announced the appointment of Dr. Rob Winn, MD, as the next Cancer Center […]
AI Summary: Rob Winn has been appointed director of the NCI‑designated Fox Chase Cancer Center, taking the reins of clinical, research and strategic operations. His role will focus on strengthening translational research, patient care integration and institutional partnerships to advance the center's mission — you know, the usual: cure more cancer, argue less in committee meetings.
‘Lack of Substantial Evidence’ Leads to FDA Rejection of Aldeyra Dry Eye Disease Drug
Frank Vinluan / medcitynews - Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye dr…
AI Summary: The FDA has rejected Aldeyra’s reproxalap application, citing a lack of substantial evidence—marking the company’s third setback. Regulators did not demand a fresh, large trial but flagged inconsistent results, prompting investor angst and a slide in the stock. The decision underscores the gap between hopeful early data and regulatory standards.
Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma
esmo - Findings from the ZSAB-neoGOLP study
AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.
Trial finds vitamin D supplements don't reduce COVID severity but could reduce long COVID risk
medicalxpress - In a large, randomized trial, researchers at Mass General Brigham found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes. Results of the study are published in The Journal of Nutrition.
AI Summary: A large randomized trial found high‑dose vitamin D3 did not lower acute COVID‑19 severity but revealed a surprising signal: supplementation may reduce the risk of developing long‑COVID. The result complicates the vitamin D narrative — not a cure, perhaps a modest shield against persistent post‑infectious symptoms worthy of further investigation.